Literature DB >> 15334172

The role of the mitogen-activated protein kinase cellular signaling pathway in tumor cell survival and apoptosis.

Scott M Freeman1, Katharine A Whartenby.   

Abstract

A number of signaling pathways are important in the initiation and maintenance of tumor cell survival and growth. Mitogen activated protein kinases are a family of kinases of different lineages that are thought to be important in tumor growth and metastasis. These pathways provide insight into how tumor cells may escape killing by different agents. In addition, since these pathways are involved in tumor cell survival, several strategies to inhibit them are being tested for novel cancer therapies. This review summarizes the evidence for the role of these pathways in cancer and the current status of therapies. (c) 2004 Prous Science. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15334172     DOI： 10.1358/dnp.2004.17.4.829050

Source DB:  PubMed          Journal:  Drug News Perspect        ISSN： 0214-0934


  3 in total

1.  Differential effects of cetuximab and AEE 788 on epidermal growth factor receptor (EGF-R) and vascular endothelial growth factor receptor (VEGF-R) in thyroid cancer cell lines.

Authors:  S Hoffmann; A Burchert; A Wunderlich; Y Wang; S Lingelbach; L C Hofbauer; M Rothmund; A Zielke
Journal:  Endocrine       Date:  2007-04       Impact factor: 3.633

2.  LPLUNC1 inhibits nasopharyngeal carcinoma cell growth via down-regulation of the MAP kinase and cyclin D1/E2F pathways.

Authors:  Yixin Yang; Qianjin Liao; Fang Wei; Xiaoling Li; Wenling Zhang; Songqing Fan; Lei Shi; Xiayu Li; Zhaojian Gong; Jian Ma; Ming Zhou; Juanjuan Xiang; Shuping Peng; Bo Xiang; Hao Deng; Yunbo Yang; Yong Li; Wei Xiong; Zhaoyang Zeng; Guiyuan Li
Journal:  PLoS One       Date:  2013-05-01       Impact factor: 3.240

Review 3.  Cross-study analysis of gene expression data for intermediate neuroblastoma identifies two biological subtypes.

Authors:  Patrick Warnat; André Oberthuer; Matthias Fischer; Frank Westermann; Roland Eils; Benedikt Brors
Journal:  BMC Cancer       Date:  2007-05-25       Impact factor: 4.430
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.